ClinicalTrials.gg
CompletedNCT04904016FlowOx-MSUpdated Oct 19, 2026

Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity

An interventional study of FlowOx™ in Multiple Sclerosis, Spasticity, Muscle and Pain, sponsored by Otivio AS. Completed at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Otivio AS · Not applicable, Interventional, and Treatment

How we know

Updated Oct 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Multiple Sclerosis with a site in Norway — 2 open to participants now, 9 under way, 3 of them phase 3. Multiple Sclerosis · Norway.

Enrollment
42nd of 43
10 · median 300
Started
2021
with 2 others
No phase
9 of 56
none open now
Registered
45th of 56
by date

Among the 56 studies in Multiple Sclerosis with a site in Norway, this one is the 42nd largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2021, is one of 9 with no phase, and was the 45th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 56 studies in Multiple Sclerosis with a site in Norway are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Multiple Sclerosis with a site in Norway, or all of them as a file.
02

Study summary

This is a descriptive, prospective, non-controlled clinical investigation to be conducted on approximately 10 enrolled subjects at one site at Haukeland University Hospital in Bergen, Norway. The target subjects are male or female, 18-70 years, diagnosed with MS according to revised McDonald criteria (9) with spasticity and pain associated with the spasticity. Spasticity is evaluated based on self-reported spasticity using the numerical rating scale (NRS) which describes the average score of spasticity over the last 24 hours at >4 (where the scale scores spasticity from 0-10, where 0 is no spasticity, and 10 is worst possible spasticity), - combined with pain in the lower extremities last 24 hours. The pilot investigation is done to evaluate if FlowOx2.0™ can be used to treat spasticity with concomitant pain in patients with multiple sclerosis, using intermittent negative pressure affecting arteriovenous reflex.

03

Conditions studied

  • Multiple Sclerosis
  • Spasticity, Muscle
  • Pain

Keywords

  • Blood flow
  • FlowOx™
  • Stiffness
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnose MS according to revised McDonald criteria
  2. Give written .
  3. Have an age between 18-70 years.
  4. Have stable disease without attack or progression of loss of function in the last three months.
  5. Have self-reported spasticity, scored using the numeric rating scale (NRS) which describes the average score of spasticity over the last 24 hours, at ≥ 4 (where the scale scores spasticity from 0-10, where 0 is no spasticity, and 10 is worst possible spasticity), - combined with pain in the lower extremities last 24 hours
  6. Have tried standard treatment for spasticity and pain without achieving a satisfactory effect.
  7. Stable and unchanged treatment of spasticity and pain the last month
  8. Stable and unchanged disease-modulating treatment for MS last 6 months.
  9. Function level measured by the Expanded Disability Status Scale (EDSS) 2.0-6.5
  10. Can self-manage study equipment.

Exclusion criteria

Exclusion Criteria:

  1. Have spasticity due to a disease other than MS.
  2. Pregnancy or plan a pregnancy within the upcoming study period of 6 months.
  3. Have an ongoing infection.
  4. Have received botulinum toxin injection for spasticity within the last 4 months.
  5. Have symptoms or illness that make it difficult to participate in the study.
  6. Having planned surgery or other treatment within the coming study period of 6 months makes it difficult to participate in the study.
  7. Have functional scores outside inclusion criteria measured by EDSS 2.0-6.5
  8. Have had disease activity beyond requirements for stable disease as described in inclusion criteria
  9. Have changed drug treatment beyond requirements for stable treatment as described in inclusion criteria.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Intervention FlowOx treatment

    Each participating subject will be provided with one FlowOx™ system, which will be used about 1 hour per day every day of the week for a 4-week period with the option to extend the treatment time to up to 6 months if the patients would like to continue.

    Device: FlowOx™

Interventions

  • DeviceFlowOx™

    The FlowOx™ system generates a negative oscillating pressure which cause rapid fluctuations in blood flow in the leg and foot.

06

What researchers measure

Primary outcomes

  1. Self-Reported Spasticity, using Numerical Rating Scale:

    The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher scores mean a worse outcome. To evaluate change in self-reported spasticity using the numerical rating scale (NRS) over the last 24 hours after daily 1-hour self-treatment with FlowOx from baseline to week 4

    Time frame: 4 weeks

Secondary outcomes

  1. Desire to continue treatment

    Proportion of patients who wish to continue treatment with FlowOx beyond 4 weeks

    Time frame: 4 weeks

  2. Self-Reported Spasticity, using Numerical Rating Scale

    The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher scores mean a worse outcome. To evaluate change in self-reported spasticity using the numerical rating scale (NRS) over the last 24 hours after daily 1-hour self-treatment with FlowOx compared to baseline

    Time frame: 3 months, 6 months

  3. Spasticity - modified Ashworth Scale

    The unabbreviated scale title: Modified Ashworth Scale The minimum and maximum values: 0, 4 Higher scores mean a worse outcome. Change in spasticity measured by modified Ashworth scale from baseline to week 4, month 3 and month 6.

    Time frame: 4 weeks, 3 months and 6 months

  4. Self-reported pain using Numerical Rating Scale

    The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher score means worse pain. To evaluate change in self-reported spasticity using the numerical rating scale (NRS) over the last 24 hours after daily 1-hour self-treatment with FlowOx from baseline.

    Time frame: 4 weeks, 3 months and 6 months

  5. T25-FW

    Change of Timed 25-Foot Walk (T25-FW) from baseline

    Time frame: 4 weeks, 3 months, 6 months

  6. Expanded Disability Status Scale

    The unabbreviated scale title: Expanded Disability Status Scale The minimum and maximum values: 0, 10 Higher score means worse disability status. Change of functional score measured by Expanded Disability Status Scale (EDSS) and compared to baseline

    Time frame: 4 weeks, 3 months, 6 months

  7. Self-reported sleep (NRS)

    The unabbreviated scale title: Numerical Rating Scale The minimum and maximum values: 0, 10 Higher score means worse sleep. Change in self reported sleep quality will measured by (NRS) and compared to baseline

    Time frame: 4 weeks, 3 months, 6 months

  8. Hospital Anxiety and Depression Scale

    The unabbreviated scale title: Hospital Anxiety and Depression Scale The minimum and maximum values: 0, 3 Higher score means worse outcome. The Scale has 14 questions, the scores will be summarized at each time point and compared to baseline

    Time frame: 4 weeks, 3 months, 6 months

  9. Fatigue Scale for Motor and Cognitive Functions

    The unabbreviated scale title: Fatigue Scale for Motor and Cognitive Functions (FSMC) The FSMC is an assessment of MS-related cognitive and motor fatigue. A Likert-type 5-point scale (ranging from 'does not apply at all' to 'applies completely') produces a score between 1 and 5 for each scored question. Thus minimum value is 20 (no fatigue at all) and maximum value is 100 (severest grade of fatigue). Two subscales (mental and physical fatigue) can be made. Items included in the subscale mental are 1-4-7-8-11-13-15-17-18-20 and items included in the subscale physical are 2-3-5-6-9-10-12-14-16-19. Changes in the scores will be compared to baseline.

    Time frame: 4 weeks, 3 months, 6 months

  10. Multiple Sclerosis Impact Scale (MSIS-29)

    The unabbreviated scale title: Multiple Sclerosis Impact Scale The minimum and maximum values: 1, 5 Higher score means worse condition. There are 29 questions, change in reported status will be compared to baseline

    Time frame: 4 weeks, 3 months, 6 months

  11. SDMT

    Change in cognition measured by the Symbol Digit Modalities Test (SDMT) The Symbol Digit Modalities Test (SDMT) is a cognitive task. It consists of a sheet of paper with, at the top, a sequence of nine symbols and nine corresponding numbers (key). The task sequence consists of a series of symbols, each with a blank space underneath. Within a 90-second time limit the subject is required, consulting the key as necessary, to insert the numbers associated with the symbols. Changes in the performance will be compared to baseline.

    Time frame: 4 weeks, 3 months, 6 months

  12. Change in medication

    Medication used by the patients at the start of the trial will be recorded. Any change in frequency of use or dose of the medication to treat spasticity an/or pain will be recorded and compared to baseline.

    Time frame: 4 weeks, 3 months and 6 monhts

  13. Compliance

    "Compliance" / use of FlowOx, is automatically logged in the machine and will be read after 4 weeks

    Time frame: 4 weeks, 3 months, 6 months

  14. Safety- Incidence of device related adverse and serious adverse events

    The number and type of adverse events and servere device related events during the study will be recorded. To evaluate safety of FlowOx by assessment of device deficiencies and adverse events, non-serious and serious, rated for causality

    Time frame: 4 weeks, 3 months, 6 months

07

Study locations

1 site
  • Neuro-SysMed, Dept. of Neurology, Haukeland University Hospital, & Dept. of Clinical Medicine, University of Bergen
    Bergen, 5021, Norway
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Sep 2022, 16 months.

Of 874 interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 16 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2021 → Sep 2022 and completion Dec 2021 → Sep 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2021
First posted
May 27, 2021
StartActual
May 28, 2021
Primary completionActual
Sep 30, 2022was Dec 2021
CompletionActual
Sep 30, 2022was Dec 2021
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 19, 2026
Primary completion
Dec 2021→Sep 30, 2022 (actual)
Oct 19, 2026
Study completion
Dec 2021→Sep 30, 2022 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Status unknown→Completed
    Primary completion Dec 2021→Sep 30, 2022 (now actual)
    Study completion Dec 2021→Sep 30, 2022 (now actual)
    + 5 other changes: verification date, oversight details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04904016
Lead sponsor
Otivio AS
Responsible party
Sponsor
First posted
May 27, 2021
Start date
May 28, 2021
Primary completion
Sep 30, 2022
Completion
Sep 30, 2022
Last update
Oct 19, 2026

Study contacts

Kjell-Morten Myhr
principal investigator · Neuro-SysMed, Haukeland University Hospital, Bergen Norway

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion